Evidence map›Paper›PMID 23691202›Full record

SynthesisPloS one2013

Lenalidomide treatment for multiple myeloma: systematic review and meta-analysis of randomized controlled trials.

Bo Yang, Rui-li Yu, Xiao-hua Chi, Xue-chun Lu

2 registry-linked trialsAbstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 26 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 6 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05218603 unknown statusnot on this mapstarted 2021, after this paper: background citation

A Prospective, Observational Study, to Evaluate the Maintenance With Bortezomib Plus Daratumumab (V-Dara) After Induction With Bortezomib, Melphalan, Prednisone Plus Daratumumab (VMP-Dara) in Newly Diagnosed Multiple Myeloma (MM) Patients Non-eligible for Autologous Stem Cell Transplantation (ASCT): Alcyone-optimized Real World Evidence (RWE) Data

TypeobservationalSponsorPETHEMA FoundationRan2021 to 2025Enrolled100ConditionsMultiple Myeloma, Non-eligible for Autologous Stem Cell Transplantation (ASCT)ArmsBortezomib, Daratumumab
NCT05541978 completednot on this mapstarted 2022, after this paper: background citation

Thrombosis in Newly Diagnosed Multiple Myeloma Patients: a Clinical Audit of Intermediate Dose Low Molecular Weight Heparin

TypeobservationalSponsorCatalina CodreanuRan2022 to 2023Enrolled140ConditionsMultiple Myeloma, Venous Thromboembolism, Arterial ThromboembolismArmsMultiple myeloma
3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 6 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Article
  8. Observational
  9. Article
  10. Article
  11. Article
  12. Access to Isoquinolin-2(1The Journal of organic chemistry · 2022
    Article
  13. Cancer Therapy-Associated Thrombosis.Arteriosclerosis, thrombosis, and vascular biology · 2021
    Review
  14. Article
  15. Review
  16. Article
  17. Implications of Angiogenesis Involvement in Arthritis.International journal of molecular sciences · 2018
    Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Bo YangDepartment of Geriatric Hematology, Chinese PLA General Hospital, Beijing, China.
Rui-li Yu
Xiao-hua Chi
Xue-chun Lu

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn recent years, a number of randomized controlled trials (RCTs) have reported on lenalidomide as a treatment for multiple myeloma (MM). Herein, we report results of a meta-analysis of RCTs examining the efficacy and safety of lenalidomide for MM. PATIENTS AND

methodsDatabases were searched using the terms "lenalidomide or revlimid AND multiple myeloma."RCTs evaluating initial or maintenance therapeutic outcomes were included. Main outcome measures were response rates, progression-free survival (PFS), overall survival, and adverse events.

resultsSeven trials were included (N = 192-614 participants). Lenalidomide doses and treatment regimens differed between trials. Complete response (CR) and very good partial response (VGPR) risk ratios (RR) favored lenalidomide over placebo (CR = 2.54, 95% confidence interval [CI] = 1.29-5.02; VGPR = 2.82, 95% CI = 1.30-6.09). The PFS hazard ratio favored lenalidomide over placebo (0.37, 95% CI = 0.33-0.41). For adverse events, neutropenia, deep vein thrombosis (DVT), infection, and hematologic cancer RR favored placebo over lenalidomide (neutropenia: 4.74, 95% CI = 2.96-7.57; DVT: 2.52; 95% CI: 1.60-3.98; infection: 1.98; 95% CI: 1.50-2.62; hematologic cancer: 3.20; 95% CI: 1.28-7.98).

conclusionsLenalidomide is an effective treatment for MM; however, treatment-related adverse events must be considered and appropriate adjustments and/or prophylactic treatment should be initiated where possible.

Indexed as

Disease-Free SurvivalHumansLenalidomideMultiple MyelomaNeoplasms, Second PrimaryRandomized Controlled Trials as TopicThalidomideTreatment OutcomeLenalidomideThalidomide

Identifiers

PMID23691202
PMCPMC3653900

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.